How ECG Monitoring Detects Lacosamide-Induced Arrhythmia
Lacosamide, an antiepileptic drug used for partial-onset seizures, can prolong the PR interval on ECG, leading to atrioventricular (AV) block or other conduction abnormalities classified as arrhythmias. ECG monitoring identifies these changes by recording the heart's electrical activity over time, spotting subtle shifts that cause symptoms like dizziness, syncope, or bradycardia.[1]
What ECG Changes Signal Lacosamide Arrhythmia
Continuous or serial ECGs reveal:
- PR interval prolongation (>200 ms), often dose-dependent and reversible upon discontinuation.
- Second- or third-degree AV block in severe cases, where atrial impulses fail to reach ventricles.
- QRS widening or QT prolongation less commonly, distinguishing it from other drug-induced arrhythmias.
These patterns emerge within hours to days of starting lacosamide, especially at doses >400 mg/day or in patients with baseline conduction issues.[2][3]
Why ECG Is Essential for Diagnosis
Routine ECGs before and during treatment (e.g., at 1-3 months) catch asymptomatic PR prolongation early, preventing progression to symptomatic arrhythmia. Holter or telemetry monitoring provides 24-48 hour captures for intermittent events missed by spot checks. Without ECG, diagnosis relies on vague symptoms, delaying intervention like dose reduction or pacemaker placement.[4]
Patients at Risk and Monitoring Protocols
Higher risk in those with heart disease, elderly patients, or on beta-blockers/AV node depressants. Guidelines recommend baseline ECG, repeat at steady-state, and ongoing telemetry if PR >240 ms. FDA labeling mandates ECG monitoring due to post-marketing AV block reports.[5]
Outcomes and Management After ECG Diagnosis
Detected early, most cases resolve with lacosamide withdrawal; persistent blocks may need cardiology referral. ECG follow-up confirms reversibility, guiding safe rechallenge at lower doses.[3]
[1]: FDA Lacosamide Label
[2]: Harden CL, et al. Epilepsia 2013;54:1414-1420
[3]: Specchio LM, et al. Epilepsy Res 2012;99:154-160
[4]: EPILAR project. Eur J Neurol 2016;23:129-139
[5]: EMA Lacosamide Summary](https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf)